Recommendations for the use of everolimus in de novo kidney transplantation: false beliefs, myths and realities
Mostra el registre complet Registre parcial de l'ítem
- dc.contributor.author Pascual Santos, Julioca
- dc.contributor.author Diekmann, Fritzca
- dc.contributor.author Fernández-Rivera, Constantinoca
- dc.contributor.author Gómez-Marqués, Gonzaloca
- dc.contributor.author Gutiérrez-Dalmau, Alexca
- dc.contributor.author Pérez-Sáez, María Joséca
- dc.contributor.author Sancho-Calabuig, Asunciónca
- dc.contributor.author Oppenheimer, Federicoca
- dc.date.accessioned 2018-07-04T07:46:20Z
- dc.date.available 2018-07-04T07:46:20Z
- dc.date.issued 2017
- dc.description.abstract The immunosuppressive combination most commonly used in de novo kidney transplantation comprises a calcineurin inhibitor (CI), tacrolimus, a mycophenolic acid derivative and steroids. The evidence which underlies this practice is based in the Symphony trial with controlled follow-up of one year, in which no comparator group included the combination CI-mTOR inhibitor. Different high-quality clinical trials support the use of everolimus as a standard immunosuppressive drug associated with reduced exposure of a CI in kidney transplantation. This combination could improve health related outcomes in kidney transplantation recipients. The present recommendations constitute an attempt to summarise the scientific evidence supporting this practice, discuss false beliefs, myths and facts, and offer specific guidelines for safe use, avoiding complications.
- dc.format.mimetype application/pdf
- dc.identifier.citation Pascual J, Diekmann F, Fernández-Rivera C, Gómez-Marqués G, Gutiérrez-Dalmau A, Pérez-Sáez MJ. Et al. Recommendations for the use of everolimus in de novo kidney transplantation: False beliefs, myths and realities. Nefrologia. 2017 May - Jun;37(3):253-266. DOI: 10.1016/j.nefro.2016.11.007
- dc.identifier.doi http://dx.doi.org/10.1016/j.nefro.2016.11.007
- dc.identifier.issn 0211-6995
- dc.identifier.uri http://hdl.handle.net/10230/35022
- dc.language.iso spa
- dc.publisher Elsevierca
- dc.relation.ispartof Nefrologia. 2017 May - Jun;37(3):253-66
- dc.rights © 2016 Sociedad Española de Nefrología. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
- dc.rights.accessRights info:eu-repo/semantics/openAccess
- dc.rights.uri http://creativecommons.org/licenses/by-nc-nd/4.0/
- dc.subject.keyword Everolimus
- dc.subject.keyword Inhibidores de mTOR
- dc.subject.keyword Kidney transplant
- dc.subject.keyword Trasplante renal
- dc.subject.keyword mTOR inhibitors
- dc.subject.other Ronyons -- Trasplantació
- dc.title Recommendations for the use of everolimus in de novo kidney transplantation: false beliefs, myths and realitiesca
- dc.type info:eu-repo/semantics/article
- dc.type.version info:eu-repo/semantics/acceptedVersion